In our neighboring countries Finland and Denmark, as well as the United Kingdom, France, Germany and Slovenia, the medicine is already available for people with cystic fibrosis.
But in Sweden, all the authorities that SVT spoke to reason that the price is far too high.
But that is not the opinion of the pharmaceutical company Vertex, which developed the product.
- The prices of our medicines reflect the value they create, and the difference they mean for patients' lives, their families and society.
Developing drugs involves a very high risk and large costs, writes Eric Gillberg, Country Manager Nordics for Vertex, in an email to SVT.
SVT has applied for Minister of Social Affairs Lena Hallengren but she does not want to stand up for an interview or leave a comment about TLV's decision.
Hear the authority justify the decision in the video.